Keytruda-Padcev wins EU approval for resectable bladder cancer, any cisplatin status

Merck's Keytruda (pembrolizumab) plus Astellas Pharma's Padcev (enfortumab vedotin-ejfv) won European Commission approval on 21 October 2026 as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC) ^[1]. The clearance applies regardless of whether a patient can tolerate cisplatin, the chemotherapy that has gated neoadjuvant treatment decisions in this disease for years. Merck describes the regimen as the first and only PD-1 inhibitor plus antibody-drug conjugate combination approved in the EU for MIBC without a cisplatin-eligibility restriction ^[1].

Why it matters

Perioperative therapy wraps around surgery: treatment before cystectomy and treatment after. The cisplatin-eligibility line has split MIBC patients into those who get platinum-based neoadjuvant chemotherapy and those who, because of renal function, hearing loss or performance status, cannot. The EU decision gives both groups the same chemo-free immunotherapy-plus-ADC backbone in the curative-intent window ^[1]. For a European urologic-oncology program, the comparator in treatment-naive resectable disease shifts from cisplatin alone to a combination with a regulatory label covering the whole resectable population.

The approval follows the same combination's US path. The FDA approved pembrolizumab, or the subcutaneous co-formulation Keytruda Qlex (pembrolizumab plus berahyaluronidase alfa-pmph), each with enfortumab vedotin on 10 July 2026 ^[2]. Pembrolizumab (BLA 125514) is on file with the FDA under Merck Sharp Dohme ^[3][4]. The EU now mirrors a combination already cleared in the US market.

Who is exposed

The marketed urothelial incumbents sit in later settings. Nivolumab's DailyMed label covers locally advanced or metastatic urothelial carcinoma after disease progression on platinum-containing chemotherapy ^[5]. Erdafitinib (Balversa) is labeled for FGFR3-altered locally advanced or metastatic disease after at least one prior line of systemic therapy ^[6]. Both operate in metastatic or relapsed disease; the EU decision plants pembrolizumab plus enfortumab vedotin in the resectable, curative-intent setting ahead of them. A metastatic-stage asset does not directly compete for the perioperative patient. It does inherit a population that will increasingly have seen a PD-1 inhibitor and an ADC before recurrence, which narrows the rationale for re-treating with the same mechanisms later.

What to watch

Prognyx worked from Merck's announcement. No European Commission decision document or EU medicines register number was in the public record Prognyx reviewed, and no EMA assessment report was available to confirm the exact wording of the approved indication. The trial behind the regimen, KEYNOTE-B15/EV-304 (NCT04700124), is named in the FDA record, but its current registry status was not confirmed here ^[2]. Watch for the EMA's published product information and assessment report, which will fix the approved population and any subgroup restrictions the press release does not spell out.

The now-what

For a biotech with a urothelial program, three moves are on the table. First, re-baseline any resectable-MIBC trial: a chemo-free immunotherapy-plus-ADC regimen with an all-comers cisplatin label now carries a European perioperative approval, and a cisplatin-only control arm will be hard to justify to investigators and ethics committees. Second, reassess metastatic-line assets for sequencing: patients entering metastatic care in Europe will increasingly arrive with prior PD-1 and ADC exposure, so later-line value rests on a different mechanism or on biomarker selection. Third, for FGFR-directed or other targeted programs, the resectable setting is now occupied by a broad combination, so the clearest differentiation is a molecularly defined subgroup the approved regimen does not address.

Verdict: a structural shift in European resectable MIBC, high relevance for any urothelial developer, and the window to adjust trial design and positioning is now, before the EMA label text sets the competitive boundaries.